Immunotherapy in Sarcoma & LMS
Evidence, clinical trials, and expert presentations on immunotherapy approaches for sarcoma and leiomyosarcoma.
Overview
Immunotherapy for Sarcoma & LMS
Curated links and resources for easy reading
Immunotherapy is an evolving area of cancer treatment that harnesses the body's own immune system to fight disease. Research into its application for sarcomas — including leiomyosarcoma — is advancing through clinical trials, checkpoint inhibitor studies, and novel vaccine approaches. Below you will find curated resources covering the latest findings, expert video presentations, and foundational information on immunotherapy in the sarcoma context.
LMS Immunotherapy Updates & Clinical Trials
Research & Trial Results
Key publications and clinical trial data
Avelumab + Trabectedin
Treating patients with liposarcoma or leiomyosarcoma that is metastatic or cannot be removed by surgery.
ClinicalTrials.gov · NCT03074318M2-Macrophage Infiltration & PD-L1
Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high-grade leiomyosarcomas supports immunotherapeutic strategies.
PubMedPD-L1 & Immunotherapy Overview
White paper covering PD-L1 biology and its role in immunotherapy treatment approaches.
Discover Care BelieveImmune Profiling of Sarcomas
First extensive immune profiling of sarcomas shows some likely susceptible to immunotherapy.
Fred HutchExceptional Responder to Pembrolizumab
Guides immunotherapy progress in leiomyosarcoma based on an exceptional response case.
OncLivePRAME Overexpression
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.
Clinical Sarcoma ResearchNivolumab Phase 2 Study
Immunotherapy with single-agent nivolumab for advanced leiomyosarcoma of the uterus — results of a phase 2 study.
PubMedImmunotherapy Promise for Sarcomas
How existing and emerging immunotherapy treatments could be successful for sarcomas, particularly LMS and pleomorphic sarcoma.
News MedicalWeb Presentations
Immunotherapy for sarcoma & leiomyosarcoma
Novel Sarcoma Vaccine
Immune responses from early study of a novel sarcoma vaccine.
Fred HutchNivolumab for uLMS
Phase 2 results for single-agent nivolumab in advanced uterine leiomyosarcoma.
PubMedPRAME in Sarcoma
PRAME as a potential immunotherapy target across sarcoma subtypes.
Clinical Sarcoma ResearchCRI Immunotherapy Webinars
Monthly webinar series from Cancer Research Institute
The full series of monthly immunotherapy webinars from Cancer Research Institute, covering the latest advances across cancer types.
Browse CRI WebinarsExpert Videos
Expert Presentations
Key video presentations from Drs. Singh, Chmielowski, Wilky, and George
An Early-Stage Trial of Immunotherapy for Advanced Sarcomas
Dr. Arun Singh · 2015
Leiomyosarcoma: Immunotherapy Clinical Trials
Dr. Bartosz Chmielowski · 2017
Dr. Wilky on Immunotherapy Trial in Sarcoma
Dr. Breelyn Wilky · 2017
Efficacy With PD-1 Inhibitor in Uterine Leiomyosarcoma
Dr. Suzanne George · 2017
Foundational Resources
NCI & CRI Resources
Foundational information on immunotherapy from leading institutions
Immunotherapy to Treat Cancer
Comprehensive NCI resource on immunotherapy types, how they work, and side effects.
National Cancer InstituteImmunotherapy for Sarcoma
How immunotherapy is changing the outlook for patients with sarcoma.
Cancer Research InstituteCRI Monthly Webinars
Monthly immunotherapy webinar series covering the latest advances from CRI.
Cancer Research InstituteCheckpoint Inhibitors
Checkpoint Inhibitors for LMS
Currently being explored as a treatment approach for leiomyosarcoma
Checkpoint inhibitors work by blocking proteins that prevent the immune system from attacking cancer cells. Researchers are actively investigating their use in leiomyosarcoma, with ongoing clinical trials evaluating their efficacy both as monotherapy and in combination with other agents.
Search Immunotherapy Clinical Trials